静注用免疫グロブリン製剤の世界市場

◆英語タイトル:Global Intravenous Immunoglobulins Market 2017-2021
◆商品コード:IRTNTR13212
◆発行会社(調査会社):Technavio
◆発行日:2017年5月31日
◆ページ数:70
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:グローバル
◆産業分野:医療・製薬
◆販売価格オプション(消費税別)
Single User(1名利用)USD3,500 ⇒換算¥385,000見積依頼/購入/質問フォーム
Five User(~5名利用)USD4,000 ⇒換算¥440,000見積依頼/購入/質問フォーム
Enterprise License(全社内共有可)USD5,000 ⇒換算¥550,000見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※納期:即日~2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・郵送(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
当調査レポートでは、静注用免疫グロブリン製剤の世界市場について調査・分析し、エグゼクティブサマリー、市場概観、市場概観、業界の構造分析、静注用免疫グロブリン製剤の世界市場規模及び予測、地域別分析/市場規模、市場の成長要因、市場の課題、製品パイプライン分析、市場動向、競争状況、主要企業(ベンダー)分析などの情報をお届けいたします。
【レポートの概要】

About Intravenous Immunoglobulins
Immunoglobulins are glycoprotein molecules produced by plasma cells. They are a critical part of a body’s immune response and they do so by specifically recognizing and binding to microbes and destroying them. These immunoglobulins are produced by a body naturally, but due to some genetic or infectious diseases, the natural production of immunoglobulin is inhibited, resulting in an immune-compromised condition.

Technavio’s analysts forecast the global intravenous immunoglobulins market to grow at a CAGR of 7.62% during the period 2017-2021.

[Covered in this report]
The report covers the present scenario and the growth prospects of the global intravenous immunoglobulins market for 2017-2021. To calculate the market size, the report considers sales from both generic and branded drugs.

The market is divided into the following segments based on geography:
• Americas
• APAC
• EMEA

Technavio’s report, Global Intravenous Immunoglobulins Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

[Key vendors]
• CSL Behring
• Grifols
• Octapharma
• Shire

[Other prominent vendors]
• ADMA Biologics
• Bayer
• Bharat Serum and Vaccines
• Biotest AG
• China Biologic Products
• Hualan Biological Engineering
• Kedrion Biopharma
• LFB Group
• Sanquin

[Market driver]
• Growing number of fractionating units
• For a full, detailed list, view our report

[Market challenge]
• Complex and cost-intensive manufacturing
• For a full, detailed list, view our report

[Market trend]
• Monetary support to plasma donors
• For a full, detailed list, view our report

[Key questions answered in this report]
• What will the market size be in 2021 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?

*** You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.

【レポートの目次】

Table of Contents
PART 01: Executive summary

PART 02: Scope of the report

PART 03: Research Methodology

PART 04: Introduction
• Market outline

PART 05: An overview of diseases treated using intravenous immunoglobulins

PART 06: Market landscape
• Market overview
• Five forces analysis

PART 07: Pipeline landscape

PART 08: Market segmentation by Therapy area
• Global intravenous immunoglobulins market by neurology
• Global intravenous immunoglobins market for hematology
• Global intravenous immunoglobins market for immunology
• Global intravenous immunoglobins market for others

PART 09: Geographical segmentation
• Intravenous immunoglobulins market in Americas
• Intravenous immunoglobulins market in EMEA
• Intravenous immunoglobulins market in APAC

PART 10: Decision framework

PART 11: Drivers and challenges
• Market drivers
• Market challenges

PART 12: Market trends
• Shift in manufacturing facilities to low-cost regions
• Monetary support to plasma donors

PART 13: Vendor landscape
• Competitive scenario

PART 14: Key vendor analysis
• CSL Behring
• Grifols
• Octapharma
• Shire
• Other prominent vendors

PART 15: Appendix
• List of abbreviations

[List of Exhibits] Exhibit 01: Major diseases treated using intravenous immunoglobins therapy
Exhibit 02: Global intravenous immunoglobulins market snapshot
Exhibit 03: Global intravenous immunoglobins market 2016-2021 ($ millions)
Exhibit 04: Opportunity analysis in global intravenous immunoglobulins market
Exhibit 05: Five forces analysis
Exhibit 06: Pipeline analysis of vendors
Exhibit 07: Key clinical trials 2016
Exhibit 08: Global intravenous immunoglobulin market by therapy area 2016
Exhibit 09: Global intravenous immunoglobins market for neurology 2016-2021 ($ million)
Exhibit 10: Global intravenous immunoglobins market by hematology 2016-2021 ($ million)
Exhibit 11: Global intravenous immunoglobins market for immunology 2016-2021 ($ million)
Exhibit 12: Global intravenous immunoglobins market for others 2016-2021 ($ million)
Exhibit 13: Global intravenous immunoglobulin market by geography 2016 and 2021
Exhibit 14: Global intravenous immunoglobulin market by geography 2016-2021 ($ millions)
Exhibit 15: Market scenario in Americas
Exhibit 16: Intravenous immunoglobulins market in Americas 2016-2021 ($ millions)
Exhibit 17: North America: Percentage of global fractionation capacities 1999-2012
Exhibit 18: Market Scenario in EMEA
Exhibit 19: Intravenous immunoglobulins market in EMEA 2016-2021 ($ million)
Exhibit 20: Europe: percentage of global fractionation capacities 1999-2012
Exhibit 21: Market Scenario in APAC
Exhibit 22: Intravenous immunoglobulins market in APAC 2016-2021 ($ million)
Exhibit 23: APAC: Percentage of global fractionation capacities 1999-2012
Exhibit 24: Fractionation capacities of key vendors
Exhibit 25: Factors contributing to overall cost of immunoglobulin production
Exhibit 26: Various side-effects associated with immunoglobulin therapy
Exhibit 27: Regulatory requirements for TGA approval
Exhibit 28: Fractionating capacities globally 2007 and 2012
Exhibit 29: Competitive structure analysis of global intravenous immunoglobulins market 2016
Exhibit 30: Competitive factors in global intravenous immunoglobulins market
Exhibit 31: Market penetration of manufacturers of intravenous immunoglobulins worldwide 2016
Exhibit 32: Strategic success factors of companies in global intravenous immunoglobulins market
Exhibit 33: Key news in IVIG market
Exhibit 34: CSL Behring: Key Highlights
Exhibit 35: CSL Behring: Strength assessment
Exhibit 36: CSL Behring: Strategy assessment
Exhibit 37: CSL Behring: Opportunity assessment
Exhibit 38: Grifols: Key highlights
Exhibit 39: Grifols: Strength assessment
Exhibit 40: Grifols: Strategy assessment
Exhibit 41: Grifols: Opportunity assessment
Exhibit 42: Octapharma: Key highlights
Exhibit 43: Octapharma: Strength assessment
Exhibit 44: Octapharma: Strategy assessment
Exhibit 45: Octapharma: Opportunity assessment
Exhibit 46: Shire: Key highlights
Exhibit 47: Shire: Strength assessment
Exhibit 48: Shire: Strategy assessment
Exhibit 49: Shire: Opportunity assessment



【掲載企業】

CSL Behring, Grifols, Octapharma, Shire, ADMA Biologics, Bayer, Bharat Serum and Vaccines, Biotest AG, China Biologic Products, Hualan Biological Engineering, Kedrion Biopharma, LFB Group, and Sanquin.

【レポートのキーワード】

静注用免疫グロブリン製剤

【調査方法】

一次資料による調査(業界専門家、ベンダー、代理店、顧客等を対象にしたデプスインタビュー調査など)及び二次資料による調査(Technavio独自のプラットフォーム、産業書籍、企業報告書、ニュース記事、アナリストレポート、貿易協会、政府機関発行データなど)

★調査レポート[静注用免疫グロブリン製剤の世界市場] (コード:IRTNTR13212)販売に関する免責事項を必ずご確認ください。
★調査レポート[静注用免疫グロブリン製剤の世界市場]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆